Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
暂无分享,去创建一个
R. Greil | K. Harrington | A. Psyrri | D. Rischin | R. Swaby | B. Burtness | N. Ngamphaiboon | B. Hughes | R. Mesía | A. Bratland | D. Soulières | T. Fuereder | M. Tahara | P. Neupane | T. Rordorf | N. Basté | W. Z. W. Ishak | B. Gumuscu | J. Ge | G. D. Castro